Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - irbesartan, quantity: 75 mg - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; microcrystalline cellulose; povidone; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: hypromellose; lactose monohydrate; purified talc; microcrystalline cellulose; titanium dioxide; hyprolose; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; macrogol 6000 - indicated for the treatment of hypertension. indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (greater than or equal to 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; croscarmellose sodium; lactose monohydrate; hypromellose; microcrystalline cellulose; titanium dioxide; purified talc; macrogol 6000; colloidal anhydrous silica - indicated for the treatment of hypertension. indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (greater than or equal to 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate; purified talc; hyprolose; hypromellose; magnesium stearate; macrogol 6000; croscarmellose sodium; titanium dioxide - indicated for the treatment of hypertension. indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (greater than or equal to 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -